Depending on tumor grade and location, SST2 was observed in 45%–100% of colorectal carcinomas (Qiu et al., 2006; Evangelou et al., 2012) and in 41%–67% of HCCs (Blaker et al., 2004; Reynaert et al., 2004; Verhoef et al., 2008); SST2 was expressed in 20%–79% of breast cancers (Pilichowska et al., 2000; Orlando et al., 2004; Kumar et al., 2005; Fischer et al., 2008; Lupp et al., 2011; Frati et al., 2014), in 57% of cervical carcinomas, in 39% of endometrial cancers (Schulz et al., 2003), and in 30% of ovarian carcinomas (Hall et al., 2002; Schulz et al., 2003). This evidence concerns the gene CORT and ovarian carcinoma.